© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
ARTICLE |
Clinically Relevant Pneumonitis After Sequential Paclitaxel-Based Chemotherapy and Radiotherapy in Breast Cancer Patients
Affiliations of authors: Departments of Radiation Oncology (TKY, EAS, GHP, NRS, MDM, TAB), Radiology (GJW), Biomathematics (HDT), and Breast Medical Oncology (AUB, SWK, EST, GNH), The University of Texas M. D. Anderson Cancer Center, Houston, TX
Correspondence to: Thomas A. Buchholz, MD, Department of Radiation Oncology, Unit 97, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (e-mail: tbuchhol{at}mdanderson.org)
Background: Taxane-based chemotherapy has been associated with an increased risk of radiation pneumonitis in patients with breast cancer. To obtain additional information about this association, we investigated the association between paclitaxel chemotherapy and radiation pneumonitis in patients participating in a phase III randomized study. Methods: Five hundred and twenty-four breast cancer patients were prospectively and randomly assigned to receive either four cycles of paclitaxel followed by four cycles of 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) or eight cycles of FAC. One hundred and eighty-nine of these patients (100 in the paclitaxel–FAC group and 89 in the FAC group) subsequently underwent radiation therapy in our institution and had medical records available to review for pulmonary symptoms. In addition, a radiologist who was unaware of the type of treatment scored chest x-ray changes after radiation treatment. Crude rates of radiation pneumonitis were compared with chi-square or Fisher's exact test, and actuarial rates were assessed with Kaplan–Meier and log-rank tests. All statistical tests were two-sided. Results: No difference in the rate of clinically relevant radiation pneumonitis was observed between the two groups (5.0% in the paclitaxel–FAC group versus 4.5% in the FAC group; difference = 0.5%, 95% CI = –6.6% to 5.5%; P = 1.00). Oral steroids for pneumonitis were taken by two patients in the paclitaxel–FAC group but by none in the FAC group, and no patient was hospitalized for or died of radiation pneumonitis. The paclitaxel–FAC group (39.3%) had a higher rate of radiographic changes after irradiation than the FAC group (23.7%; difference = 15.6%, 95% CI = –0.11% to 28.8%; P = .034). Conclusion: Patients with breast cancer treated with sequential paclitaxel, FAC, and radiation therapy appeared to have a very low rate of clinically relevant radiation pneumonitis that was no different from that of patients treated with FAC alone.
CiteULike 
Connotea 
Del.icio.us What's this?
Related Memo to the Media
- Press Release: Paclitaxel Chemotherapy for Breast Cancer Not Associated With Serious Radiation Pneumonitis
- Sarah L. Zielinski
J Natl Cancer Inst 2004 96: 1643.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  M. Y. Halyard, T. M. Pisansky, A. C. Dueck, V. Suman, L. Pierce, L. Solin, L. Marks, N. Davidson, S. Martino, P. Kaufman, et al. Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831 J. Clin. Oncol., June 1, 2009; 27(16): 2638 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Haston, M. Begin, G. Dorion, and S. M. Cory Distinct Loci Influence Radiation-Induced Alveolitis from Fibrosing Alveolitis in the Mouse Cancer Res., November 15, 2007; 67(22): 10796 - 10803. [Abstract] [Full Text] [PDF]
|
|